retatrutide trial update october 2025 Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced. In Weight loss with retatrutide as

As glucose levels decrease, insulin secretion decreases, which reduces the risk of hypoglycemia compared with sulfonylureas

Aging Dis

At 3 weeks follow-up, HR with liraglutide was significantly elevated compared with placebo (n = 17) for the whole 24-h period, day- and nighttime (least squares mean differences were 5.2, 4.6, and 7.3 bpm, respectively) [26]

The extracted data included characteristics of the study cohort, study design, details of specific interventions (drugs and dosing) and pharmacokinetic outcomes

This test provides no guarantees about medication response but may help explain individual differences in tolerance and efficacy

Commenting on the study, Hannah Beba, clinical lead for obesity at the West Yorkshire Health and Care Partnership, called the retatrutide topline results genuinely striking, noting that the 30% weight loss was a level long associated with bariatric surgery